According to a report on NJ.com, advancements in cancer research have dramatically increased survival rates; in fact, there are currently over 12 million cancer survivors in the United States thanks to the development of early detection screening and effective treatments.
Since 1983, the state of New Jersey has provided funding for the New Jersey Commission on Cancer Research (NJCCR). The NJCCR promotes original research in the causes, prevention, and treatment of cancer and has awarded millions of dollars in grants for student fellowships, peer-reviewed scientific research, and other research and development opportunities. The Commission also uses funds to support new scientists at various NJ research institutions. Unfortunately, the state funding and therefore the ability to award grants and provide other essential support to cancer research programs has been slashed due to cuts in the New Jersey State budget.
State cuts include $1 million of funding that was originally appropriated for the NJCCR. Without these funds, the Commission will find it difficult to award grants and provide assistance to scientists and research institutions as it has in the past. It is the hope of the Commission that funding will be restored.
The funding of cancer research is a very important element in combating this disease in all its forms. However, the most important factors in a cancer patient’s prognosis are accurate and timely diagnosis and effective treatment. Without timely diagnosis and effective treatment a patient cannot benefit from advancements in cancer research.
If you or a loved one has suffered as the result of a healthcare professional’s failure to diagnose your cancer accurately or in a timely manner or their failure to effectively treat your cancer, you may be entitled to pursue civil action.
To discuss your potential claim with one of the experienced New Jersey delayed cancer diagnosis attorneys at Blume Forte, call us at (973) 635-5400 for a no-cost consultation. We can help you understand your legal rights and potential options.